Close Menu

IVF

Researchers from Italy's Genoma Molecular Genetics Laboratory in Rome have published a validation of an Illumina sequencing method for preimplantation genetic diagnosis and screening that they said reflects closely the methodology behind the VeriSeq commercial PGS test Illumina p

Reproductive Medicine Associates of New Jersey is currently enrolling patients in a clinical validation trial of targeted next-generation sequencing-based preimplantation genetic testing to aid in the selection of embryos for transfer as part of in vitro fertilization.

This article was originally published on Jan. 29.
Microarrays are still a growing business for Illumina.

This article has been corrected to reflect that Illumina will seek Chinese FDA approval for a MiSeqDx-based NIPT assay, not a HiSeq2500-based assay, as previously reported.

Oxford Gene Technology this week launched a new microarray that can be used to screen embryos for chromosomal abnormalities prior to implantation during an in vitro fertilization cycle.

This story was originally posted on March 7

Illumina's acquisition of BlueGnome has provided a boost for its array business.

This story was originally posted on Oct. 24

Good Start Genetics has expanded the disorders it covers in its sequencing-based preconception carrier screening service to 23 after launching a more limited panel in April.

This article has been updated from a version posted Sept. 19 to include comments from Illumina officials.

Pages

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.